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It appears that patients with advanced stages of chronic obstructive pulmonary disease, and particularly 
emphysema, lose weight and have higher mortality even after controlling for lung function. In the 
present study, mortality of a,-antitrypsin-deficiency patients PiZ as a function of body mass index (BMI) 
with control for FEV,, sex and smoking habits was studied. A total of 342 patients participated with a 
mean follow-up time of 7.6 yr. Ninety patients had BMI under 20 kg rnp2, which was the cut-off defining 
underweight patients. The patients were divided into three groups according to their initial FEV, % 
predicted: <30%, 30-64% and 2 65%. The underweight patients had significantly higher mortality in the 
two groups with the lowest FEV, % predicted. A Cox regression model was applied to control for 
potential confounders. The risk ratio for the underweight patients was 1.6 (P=O.O3) after controlling for 
FEV1, age, sex and smoking habits. It is concluded that low body weight is an independent predictor of 
mortality, but the reason is still unclear. 
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Introduction 
The hereditary disorder a,-antitrypsin deficiency 
(a1ATD) is associated with early onset emphy- 
sema and premature death, with smoking being 
the most important additional risk factor. 
Impaired lung function in terms of low forced 
expiratory volume in 1 s (FEV,) is the most 
significant predictor of mortality, but current 
smokers also have a significantly worse prog- 
nosis as compared to ex-smokers (1). 
It is well known that patients with severe 
chronic obstructive pulmonary disease (COPD), 
particularly emphysema, lose weight in advanced 
stages of the disease. It is also known that in 
patients with severe COPD and emphysema, low 
body weight is associated with increased mor- 
tality (2), and it has been suggested by Wilson et 
al. (3) that weight loss is a predictor of mortality 
independent of lung function. 
The purpose of the present study was to 
evaluate mortality as a function of body mass 
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index (BMI) in subjects with severe alATD 
followed for up to 18 yr. 
Patients and Methods 
Patients were selected from The Danish a,- 
Antitrypsin Deficiency Register in Copenhagen. 
Since 1978, patients have been registered by 
physicians throughout Denmark, and once a 
patient is registered, a family record is obtained 
and members at risk of having a Z gene are 
offered an examination of their Pi type. Index 
cases are patients ascertained because of pul- 
monary symptoms, and non-index cases are 
persons ascertained through family studies. 
More than 3500 family members of index cases 
have been tested, and by 30 June 1995, the 
register contained 698 persons with severe 
alATD, of whom 387 were index cases and 311 
were non-index cases. 
Determination of a,-antitrypsin Pi type was 
usually verified by the Department of Clinical 
Chemistry at Bispebjerg Hospital by isoelectric 
focusing, as described by Fagerhol and Cox (4). 
If phenotyping had not been performed, the 
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patients were assumed to have phenotype PiZ or 
PiZO if their a,-antitrypsin serum level was less 
than 12pmoll- ’ (5). 
For the index cases, height, weight and lung 
function measurements (spirometry) were re- 
ported by the referring physician. When the 
non-index cases were ascertained, they were 
encouraged to contact their general practitioner 
for assessment of height, weight and spirometry. 
Spirometry was performed in accordance with 
European recommendations (6). Predicted 
values of FEV, were calculated according to 
European reference tables (7). Ear this study, 
the first spirometry after the patient entered the 
registry was used. 
Body mass index was calculated as the weight 
in kilograms divided by the square of the height 
in metres. The first BMI after the patient entered 
the registry was used. ‘Underweight’ was defined 
as a BMI less than 20 kg m - 2. 
Information on date of death or emigration 
was obtained from the Danish Central Popu- 
lation Register (CPR). 
Smoking status was defined as follows: 
smoker, a person who had smoked at least 20 
packs of cigarettes or at least one cigarette per 
day for at least 1 yr in their life time (8); 
ex-smoker, a person who had abstained from 
smoking for at least 3 months. 
Patients eligible for the present study were 
identified as Pi-type ZZ or with serum level of 
a,-antitrypsin of less than 12,~~moll- ‘. The 
patient’s status (i.e. dead, alive or emigrated) at 
the closing date of the study (30 June 1995) 
should be known, height and weight data should 
be available and at least one spirometry should 
have been performed, after entry in the register. 
Furthermore, the patients should be over 20 
years old at the closing date. 
Of the 698 patients in the register, 112 were 
PiSZ (99) or had a serum alAT greater than 
12 pmol I- ’ (13). Thirty-two patients were 
under 20 years of age at the end of the study. Of 
the remaining 554 subjects, 111 had insufficient 
data on weight or height, 92 had no spirometric 
data and smoking history was unavailable for 
nine patients, leaving 342 patients for analysis 
(253 verified PiZ and 89 with a,-antitrypsin level 
of less than 12 pmol l- ‘). There were no differ- 
ences in age, sex or the number of index cases 
and non-index cases between the included and 
excluded patients, but the 212 excluded patients 
had significantly shorter follow-up times (7.6 vs. 
4.9 yr; P<O.OOl). Survival analysis revealed a 
better survival in the included group (P<O*Ol, 
log-rank test). 
Statistics 
Cumulative survival probabilities were estimated 
using the Kaplan-Meier method, and differences 
in survival were calculated with the log rank test 
(9). The period of follow-up for survival calcu- 
lation was taken from the time of the first lung 
function measurement to the date of death, 
emigration, lung transplantation or 30 June 
1995, whichever came first. The t-test was used 
to evaluate differences in FEV,, age and 
follow-up time, and the Chi-square test was used 
to test dichotomous variables. Cox proportional 
hazards regression model with time-dependent 
variables was used to analyse the influence of 
low BMI on survival, and control for smoking 
history, FEV,, gender and age (9). 
Results 
The study population comprised an equal 
number of males and females. The mean age at 
entry was 45 years, and the subjects were fol- 
lowed up for an average of 7.6 yr. During the 
study period, 107 patients died, three emigrated 
and 29 received a lung transplant. Ninety (26%) 
patients had a BMI under 20 kg m - 2 and were 
classified as underweight. In Table 1, demo- 
graphic data of the study population stratified 
for BMI are shown. The mean follow-up time 
was 6.8 yr for the underweight patients and 
7.8 yr for the patients with BMI over 20 kg m - 2 
(P=O.O7). Age at entry was similar in the two 
weight groups. Significantly more women than 
men were underweight (P<O.Ol), and a signifi- 
cantly higher percentage were current smokers 
in the underweight group (P<O*Ol). The mean 
initial FEV, % predicted was 38% (SD=21) for 
the underweight patients, and 57% (SD=30) 
for the rest (P<O-001). 
As FEV, is a strong determinant of mortality, 
the patients were classified into three groups 
based on FEV, % predicted: <30%, 30-64% and 
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TABLE 1. Demographic data of the study population stratified for body mass index 
Total 
Body mass index Weight groups 
compared 
<20 220 (P value) 
n (%) 
Sex, men/women 
Smoking history 
Current smokers 
Ex-smokers 
Never-smokers 
FEV, % predicted, mean (SD) 
Age at entry (years), mean (SD) 
Follow-up time (yr), mean (SD) 
342 (100%) 
172/170 
84 (25%) 
205 (60%) 
53 (15%) 
52.1 (29.5) 
45.5 (10.7) 
7.6 (4.4) 
90 (26%) 
34156 
35 (39%) 
44 (49%) 
11 (12%) 
37.8 (20.6) 
46.1 (11.9) 
6.8 (3.6) 
252 (74%) 
138/114 co.01 
co.01 
49 (19%) 
161 (64%) 
42 (17%) 
57.2 (30.4) <O.OOl 
45.2 (10.2) 0.5 
7.8 (4.6) 0.07 
TABLE 2. Number of dead and censored (emigrated, transplanted or alive at the end of 
follow-up) patients by body mass index and stratified for FEV, 
Body mass index 
<20 220 Total 
FEV, % predicted 
<30% Dead 
Censored 
Total 
30-64% Dead 
Censored 
Total 
265% Dead 
Censored 
Total 
26 (70%) 
11 (30%) 
37 (100%) 
18 (39%) 
28 (61%) 
46 (100%) 
1 (14%) 
6 (86%) 
7 (100%) 
22 (41%) 
32 (59%) 
54 (100%) 
32 (29%) 
78 (71%) 
110 (100%) 
8 (9%) 
80 (91%) 
88 (100%) 
48 (53%) 
43 (47%) 
91 (100%) 
50 (32%) 
106 (68%) 
156 (100%) 
9 (9%) 
86 (91%) 
95 (100%) 
265%. In Table 2, the number of dead and 
censored patients by FEV, % predicted and BMI 
are shown. In the group of patients with FEV, 
less than 30% predicted, 41% were underweight 
compared with 29% in the middle FEV, group 
and 7% in the group of patients with FEV, 
over 65% predicted (P<10.01). Figure 1 shows 
KaplanMeier plots for the group of patients 
with FEV, ~30%. Mortality was significantly 
higher in the underweight group (PzO.01, log- 
rank test). Also, as shown in Fig. 2, in the group 
of patients with FEV, % predicted between 30 
and 64%, underweight patients had significantly 
higher mortality (PzO.04). For patients with 
FEV, above 65%, there was no significant differ- 
ence in mortality between the two weight groups 
(Fig. 3). 
This increased mortality in patients with low 
BMI could be explained by differences in sex and 
smoking habits. To control for this, a Cox propor- 
tional hazards model was applied to the data. 
Smoking status was entered as two dummy vari- 
ables: a variable coded 1 for never-smokers and 0 
otherwise; and a time-dependent variable coded 1 
if the patient quit smoking during the follow-up 
period or had quit before entering the study. Thus, 
if a patient quit smoking during the study period, 
the variable would change from 0 to 1 at the time 
of smoking cessation. Additional parameters 
included in the model were FEV, % predicted, sex 
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FIG. 1. Kaplan-Meier plots of patients with an 
initial FEV, % predicted less than 30%. ~ 
’ body mass index (BMI) 2 20; - - -, BMI ~20. 
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FIG. 2. Kaplan-Meier plots of patients with an 
initial FEV, % predicted between 30 and 64% 
predicted. -, body mass index (BMI) 220; 
---, BMI ~20: 
and age. In Table 3, the result of the analysis is 
shown. Underweight patients had significantly 
higher mortality with a risk ratio of 1.6 after 
controlling for FEV,, smoking habits, sex and age 
(P=O.O3). It is seen that FEV, is a very strong risk 
factor for mortality, with a risk ratio of 8.1 for 
patients with a FEV, less than 30% predicted. 
Patients who quit smoking had significantly lower 
mortality compared with patients who continued 
to smoke, and it was also shown that never- 
smokers had increased mortality but not signifi- 
cantly. Mortality increased significantly with 
,increasing age, and men had an excess mortality 
with a relative risk of 1.6 (P=O-03). 
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FIG. 3. Kaplan-Meier plots of patients with an 
initial FEV, % predicted more than 65% pre- 
dicted. ~ body mass index (BMI) 220; 
---, BMI <2b. 
TABLE 3. Cox regression analysis with risk ratio and 
95% confidence interval (95% CI) 
Parameter Risk ratio 95% CI P value 
Body mass index 
<20 
220 
Sex 
Men 
Women 
FEV, % predicted 
<30 
30-64 
265 
Smoking history 
Current smokers 
Quitters 
Never-smokers 
Age 
1.63 1.05-2.53 0.03 
1 
1.62 1.06-2.47 0.03 
1 
8.09 3.65-17.9 <O.OOl 
3.26 1.53-6.95 0.002 
1 
1 
0.42 0.26-0.69 co.00 1 
1.60 0.85-2.99 0.14 
1.06 1.0441.08 <O.OOl 
Discussion 
This study clearly shows that underweight 
patients with emphysema have a worse prog- 
nosis than patients who are not underweight. In 
a previous study of alATD patients, reduced 
FEV, was found to be a strong determinant of 
mortality. Furthermore, improved survival after 
smoking cessation with control for FEV, was 
found, and it has also been shown that this was 
most likely due to slower decline in FEV, (1,lO). 
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Therefore, it is important to control for FEV, 
and smoking cessation in evaluating mortality 
according to weight. Even after controlling for 
this, and after controlling for gender and age in 
addition to FEV,, underweight patients had 
increased mortality. 
The present study is limited by a large number 
of missing data and it raises the question 
whether this has caused bias, particularly selec- 
tion bias. If bias was introduced, the under- 
weight patients with a poor prognosis were more 
likely to be included in the study than under- 
weight patients with a good prognosis. That is 
unlikely because the patients were registered 
consecutively and it was attempted to gather 
as much information as possible during the 
registration. 
In a study by Wilson et al. (3), the mortality of 
COPD patients followed for up to 3 yr was 
analysed according to ideal body weight, and 
stratified for FEV, % predicted in three cate- 
gories: under 35%, 3546% and 47-60%. A sig- 
nificantly larger mortality of the underweight 
patients was found in the two high FEV, cate- 
gories alone, and the difference was highest in 
the FEV, group 47-60%. However, the study 
was limited by a short follow-up time, and no 
control for smoking habits nor gender. 
As opposed to COPD patients (a mixture 
of patients with airflow obstruction), alATD 
patients develop pure emphysema. Unlike the 
results from Wilson et al’s study, the present 
study found an increasing difference in mor- 
tality between underweight and normal-weight 
patients with decreasing FEV,. This can partly 
be explained by different study populations and 
different groups of FEV, % predicted. In the 
present study, one-quarter of the patients had an 
initial FEV, % predicted above 65%, and it was 
more appropriate to split the study population in 
broader groups according to FEV,. The data in 
the present study has been analysed with strati- 
fication for FEV, in the groups used by Wilson 
et al. No significantly increased mortality of the 
underweight patients in the 3546% group was 
found, but lack of power may be the main reason 
for this result. 
In the study by Wilson et al., additional lung 
function parameters such as diffusion capacity 
(DLCO), total lung capalcity (TLC) and exer- 
cise were found to be independently associated 
with low body weight. It was suggested that 
underweight patients are more severely affected 
by the disease than what is reflected by FEV,, 
and it was concluded that low body weight is 
an independent predictor of mortality. The 
data in the present study are not sufficient for 
stratification for additional lung function 
parameters. 
As low body weight is a strong predictor of 
mortality in emphysematous patients, the question 
arises whether it is possible to revert the process by 
supplemental feeding. A controlled study by 
Rogers et al. (11) found minor clinical improve- 
ments after provision of calorie and protein sup- 
port resulting in weight gain, but concluded that 
the intervention was too costly, time-intensive and 
of limited therapeutic significance. 
It is unclear why patients with emphysema 
lose weight and why low body weight is associ- 
ated with higher mortality. It has been suggested 
that the increased work of breathing resulted 
in increased energy expenditure and negative 
energy balance, but this does not explain why 
not all patients with airways disease and 
increased work of breathing lose weight (12). 
It has recently been shown that circulating 
cytokines, such as TNF-cr, (cachexin), are 
increased in COPD patients (13). It was sug- 
gested that this is due to tissue hypoxaemia and 
explains why emphysematous patients are more 
likely to lose weight, since they more often have 
comprised tissue oxygenation (14). The theory 
also explains why supplemental feeding is of 
limited value, and it has been suggested that 
anti-TNF agents could be used to treat cachectic 
patients (12). 
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